Nothing said here yet.
to join the conversation.
Caribou Biosciences is back in focus after fair value estimates shifted from about US$11.86 to US$5.75 per share, echoing recent price target resets across Wall Street coverage.
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.
Despite Nobel Prize origins, Caribou has succumbed to a sector shifting its focus to in vivo CAR-T approaches.
Investing.com -- Caribou Biosciences Inc (NASDAQ:CRBU) shares tumbled as much as 40% in after-hours trading Tuesday following the company's announcement that it will discontinue its CAR-T cell therapy programs and explore strategic alternatives.
-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now.
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- --…